چكيده به لاتين
Cancer is regarded as one of the most dangerous diseases that humans confront. Although the offered approaches have some therapeutic efficacy, they are limited because of their risk to normal, healthy cells and their potential to destroy the immune system. As a result, much cancer therapy research focuses on finding effective therapies that can complement or even replace current therapies by improving efficacy and lowering unintended side effects. Photothermal therapy, which is based on the conversion of light energy into heat energy, due to its minimally invasive nature, as well as its high selectivity and precision, has attracted much attention in the treatment of cancer. Typically, in PTT, central photothermal agents (PTAs) effectively transform light energy into heat energy to produce local thermotherapy, and then induce irreversible necrosis of cancer tissues. Several types of materials have been extensively explored as PTAs, including gold nanomaterials, carbon nanomaterials, and metal sulfides. Colloidal gold indicates local plasmon surface resonance (LPSR), meaning that gold nanoparticles can absorb light at specific wavelengths. Metal–organic frameworks (MOFs) are a promising family of highly ordered crystalline porous coordination polymers (PCPs) which are made up of metal ions or clusters bridged by organic linkers. MOFs have attracted a lot of attention due to their remarkable features such as well-defined structure, ultrahigh surface area and porosity, tunable pore size, and easy chemical functionalization. These properties have led to the use of these compounds in various fields such as catalysis, sensing, energy storage, gas purification and separation, super-capacitors. In the field of cancer treatment, MOFs are widely used because of their ability to deliver anticancer drugs and central photothermal agents (PTAs) or other factors that can play an important role in cancer treatment. Bringing together all the advantages of the individual components discussed above, herein, we report Au@Cu(BDC-NH2)MOF-HER nanotherapeutic comprised of Cu(BDC-NH2)MOF with a conjugated herceptin antibody as a biologically active moiety for targeted delivery and small plasmonically active AuNPs incorporated into the pores of the Cu(BDC-NH2)MOF. For the synthesis of Au@Cu(BDC-NH2)MOF-HER, three important steps were taken: the synthesis of Cu(BDC-NH2)MOF, the loading of spherical gold nanoparticles into the MOF cavities, and the formation of a covalent bond between the MOF structure and the herceptin antibody, respectively.
